KalVista Pharmaceuticals (KALV) Enterprise Value (2016 - 2024)
KalVista Pharmaceuticals' Enterprise Value history spans 10 years, with the latest figure at -$268.3 million for Q4 2024.
- For Q4 2024, Enterprise Value changed N/A year-over-year to -$268.3 million; the TTM value through Dec 2024 reached -$268.3 million, changed N/A, while the annual FY2024 figure was -$210.4 million, N/A changed from the prior year.
- Enterprise Value for Q4 2024 was -$268.3 million at KalVista Pharmaceuticals, down from -$135.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$50.3 million in Q1 2021 and bottomed at -$268.3 million in Q4 2024.
- The 4-year median for Enterprise Value is -$91.9 million (2020), against an average of -$117.5 million.
- The largest annual shift saw Enterprise Value skyrocketed 40.22% in 2020 before it plummeted 41.39% in 2024.
- A 4-year view of Enterprise Value shows it stood at -$55.9 million in 2020, then increased by 9.96% to -$50.3 million in 2021, then tumbled by 105.07% to -$103.2 million in 2023, then plummeted by 160.09% to -$268.3 million in 2024.
- Per Business Quant, the three most recent readings for KALV's Enterprise Value are -$268.3 million (Q4 2024), -$135.8 million (Q4 2024), and -$174.3 million (Q3 2024).